Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic liver disease ...

One of the main threads running through our most-read stories of 2025—as much as ever in the medtech industry writ large—is ...

Big Pharma-backed Aktis Oncology has announced plans to go public, in the latest encouraging sign for those betting on a ...

Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD), offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program.

Two years after Gilead Sciences secured the first option on Assembly Biosciences’ entire pipeline, the pharma has decided to ...

Six people, including a former employee of investment bank Citigroup’s San Francisco office, have been charged in an $41 million insider trading and stock manipulation scheme that involves two biotech ...

After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.

Ipsen may be a recent entrant into the antibody-drug conjugate space, but the French biopharma is continuing to make up for lost time. | Ipsen may be a recent entrant into the antibody-drug conjugate ...

Hologic has put forward more data bolstering the use of its artificial intelligence programs for detecting breast cancer through mammography. | Hologic put forward another study that bolsters the use ...

Having kicked off the year with a $200 million series A, Windward Bio is ending 2025 splashing out on another clinical-stage drug. | Having kicked off the year with a $200 million series A, Windward ...

U.K.-based AstraZeneca has scored the exclusive rights to develop and commercialize the pan-KRAS inhibitor, dubbed JAB-23E73, outside China. On Jacobio’s home territory, the Beijing-headquartered ...

Susan Galbraith, AstraZeneca’s executive vice president for oncology haematology R&D, discussed the setback in a statement. Galbraith said the goal was to “reinvigorate the immune response of patients ...